Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Clin Cancer Res. 2010 Dec 22;17(8):2314–2327. doi: 10.1158/1078-0432.CCR-10-1903

Figure 6. BMS-754807 inhibits growth of TNBC tumorgrafts and causes regression in combination with chemotherapy.

Figure 6

A. 4 to 6-week-old female NOD/scid mice were transplanted with a 1mm3 piece of tumorgraft into a cleared number four mammary fat pad. When tumors reached a volume between 100-200mm3 they were randomized to receive the following treatments: vehicle, 50mg/kg BMS-754807 daily by oral gavage, 20mg/kg docetaxel weekly by intraperitoneal injection or the combination of 50mg/kg BMS-754807 daily and 20mg/kg docetaxel weekly by intraperitoneal injection. Tumor volume and body weight was measured daily. B. Untreated and treated tumors were processed in a tissue microarray (TMA) for immunohistochemical analysis. Immunohistochemistry was performed for phospho and total IGF-IR. Representative IHC staining of the treatment groups is taken at 40x magnification. C. Representative tumor sections of the treatment groups stained with hematoxylin and eosin are taken at 40x magnification. D. Quantification of BrdU incorporation per cell was done by image analysis. Data represents means ± SE of 12 representative pictures per treatment group. E and F. The percentage of Ki67/CC3-positive cells within the tumor was scored. Values represent the means ± SE of 12 representative pictures per treatment group. D-F Bars with different letters are significantly different (p<0.05) by ANOVA analyses and pairwise comparisons with Holm adjustment for multiple comparisons.